Oncomine Dx Target test approved to ID patients for Retevmo

Sept. 28, 2022—The FDA has approved Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic to aid in selecting patients with *RET*-fusion positive locally advanced or metastatic non-small cell lung cancer, *RET*-fusion positive advanced or metastatic thyroid cancer, and *RET*-mutation positive advanced or metastatic medullary thyroid cancer who may be eligible for treatment with Lilly's Retevmo (selpercatinib).

Retevmo is a selective *RET* (rearranged during transfection) kinase inhibitor and was the first therapy approved for patients with advanced *RET*-driven lung and thyroid cancers. The Oncomine Dx Target test is a next-generation sequencing–based test that can detect multiple alterations at once from a small sample size. It is also approved in Japan as a companion diagnostic for Retevmo in the same indications.

This is the Oncomine Dx Target test's first approval as a CDx for a therapy targeting *RET*-positive thyroid cancer, Thermo Fisher says, and the second approval associated with *RET*-positive NSCLC.